Catalent completes first phase of $7.3 million investment of Italian softgel facility


Catalent Pharma Solutions has completed the first phase of its $7.3 million investment to upgrade Italian facility. 


Photo ©

Catalent Pharma Solutions (Somerset, NJ) has completed the first phase of its $7.3 million investment to upgrade and expand the packaging and softgel encapsulation capabilities at its Aprilia, Italy, facility. Completed in August 2018, the first phase of the investment involved the expansion and upgrade of the facility’s integrated packaging capabilities, as well as the commissioning of the first of five new softgel encapsulation lines.

The second phase, which Catalent projects will be complete by January 2019, is the addition of the remaining four encapsulation lines, bringing the total number of lines to 23. This will significantly expand the company’s production, drying, and inspection capacity for dietary supplements.

“We have a long and proud history in softgel product development and commercial manufacturing,” said Aris Gennadios, PhD, president of Catalent Softgel Technologies, in a press release. “This investment is driven by increasing demand for nutritional and beauty products globally, and will enable Catalent to better serve these markets.”

Related Videos
woman working on laptop computer by window
Related Content
© 2024 MJH Life Sciences

All rights reserved.